Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Revance management to meet virtually with Piper Sandler » 06:51
10/03/22
10/03
06:51
10/03/22
06:51
RVNC

Revance

$27.02 /

+1.305 (+5.08%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RVNC Revance
$27.02 /

+1.305 (+5.08%)

RVNC Revance
$27.02 /

+1.305 (+5.08%)

09/22/22 Goldman Sachs
Revance initiated with a Buy at Goldman Sachs
09/09/22 Mizuho
Revance price target raised to $30 from $26 at Mizuho
09/09/22 Barclays
Revance price target raised to $35 from $22 at Barclays
09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
RVNC Revance
$27.02 /

+1.305 (+5.08%)

  • 13
    Sep
RVNC Revance
$27.02 /

+1.305 (+5.08%)

RVNC Revance
$27.02 /

+1.305 (+5.08%)

Over a week ago
Initiation
Revance initiated with a Buy at Goldman Sachs » 05:18
09/22/22
09/22
05:18
09/22/22
05:18
RVNC

Revance

$25.80 /

-0.17 (-0.65%)

Goldman Sachs analyst…

Goldman Sachs analyst Chris Shibutani initiated coverage of Revance Therapeutics with a Buy rating and $33 price target. As a commercial-stage biotechnology company focused on the development of cosmetic injectable and therapeutic neuromodulator products, the recent FDA approval of the company's lead asset Daxxify is "key, long-awaited de-risking event," Shibutani tells investors in a research note. With a label that includes the "differentiating" longer duration of effect of six months, meaningfully longer than the average 3-4 months benefit of existing products, the launch of Daxxify has the potential to be "disruptive," says the analyst. Shibutani expects the treatment to take market share and potentially help to grow "what remains a still relatively underpenetrated" cosmetic neuromodulator market.

ShowHide Related Items >><<
RVNC Revance
$25.80 /

-0.17 (-0.65%)

RVNC Revance
$25.80 /

-0.17 (-0.65%)

09/09/22 Mizuho
Revance price target raised to $30 from $26 at Mizuho
09/09/22 Barclays
Revance price target raised to $35 from $22 at Barclays
09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
09/08/22 Needham
Revance price target raised to $35 from $25 at Needham
RVNC Revance
$25.80 /

-0.17 (-0.65%)

  • 13
    Sep
RVNC Revance
$25.80 /

-0.17 (-0.65%)

RVNC Revance
$25.80 /

-0.17 (-0.65%)

Hot Stocks
Revance publishes efficacy/safety profile of DAXXIFY for injection » 08:11
09/19/22
09/19
08:11
09/19/22
08:11
RVNC

Revance

$25.96 /

-0.465 (-1.76%)

Revance Therapeutics…

Revance Therapeutics announced the publication of two peer-reviewed articles in Aesthetic Surgery Journal, the official journal of The Aesthetic Society. The publications reported the impact of DAXXIFY or DaxibotulinumtoxinA-lanm) for injection on brow position and frontalis muscle activity from a post-hoc analysis of patients in the Phase 2a forehead line study and the SAKURA open-label safety study as well as presenting the efficacy and safety of DAXXIFY analyzed by age and race based on a subgroup analysis of the SAKURA glabellar lines clinical trials. "The newly released publications in the Aesthetic Surgery Journal showcase Revance's commitment to generating novel data that helps healthcare providers more fully understand the clinical performance of DAXXIFY ," said Conor Gallagher, PhD, Vice President of Medical Affairs and Scientific Innovation at Revance. "This data demonstrates that treatment of frown lines with DAXXIFY results in an overall positive change in eyebrow position even with a modest reduction in forehead muscle activity."

ShowHide Related Items >><<
RVNC Revance
$25.96 /

-0.465 (-1.76%)

RVNC Revance
$25.96 /

-0.465 (-1.76%)

09/09/22 Mizuho
Revance price target raised to $30 from $26 at Mizuho
09/09/22 Barclays
Revance price target raised to $35 from $22 at Barclays
09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
09/08/22 Needham
Revance price target raised to $35 from $25 at Needham
RVNC Revance
$25.96 /

-0.465 (-1.76%)

  • 13
    Sep
RVNC Revance
$25.96 /

-0.465 (-1.76%)

RVNC Revance
$25.96 /

-0.465 (-1.76%)

Options
Revance put volume heavy and directionally bearish » 15:15
09/16/22
09/16
15:15
09/16/22
15:15
RVNC

Revance

$26.00 /

-0.42 (-1.59%)

Bearish flow noted in…

Bearish flow noted in Revance with 2,147 puts trading, or 1.2x expected. Most active are Oct-22 25 puts and Oct-22 30 calls, with total volume in those strikes near 2,300 contracts. The Put/Call Ratio is 1.60, while ATM IV is up nearly 5 points on the day. Earnings are expected on November 8th.

ShowHide Related Items >><<
RVNC Revance
$26.00 /

-0.42 (-1.59%)

RVNC Revance
$26.00 /

-0.42 (-1.59%)

09/09/22 Mizuho
Revance price target raised to $30 from $26 at Mizuho
09/09/22 Barclays
Revance price target raised to $35 from $22 at Barclays
09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
09/08/22 Needham
Revance price target raised to $35 from $25 at Needham
RVNC Revance
$26.00 /

-0.42 (-1.59%)

  • 13
    Sep
RVNC Revance
$26.00 /

-0.42 (-1.59%)

Hot Stocks
Revance to present Phase 2 JUNIPER data at MDS Congress » 16:07
09/15/22
09/15
16:07
09/15/22
16:07
RVNC

Revance

$26.15 /

-1.35 (-4.91%)

Revance Therapeutics at…

Revance Therapeutics at the International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain. The presentation will include results from Revance's JUNIPER Phase 2 clinical trial evaluating the efficacy and safety of three doses of DAXXIFY compared to placebo for adults with upper limb spasticity after stroke or traumatic brain injury. DAXXIFY was found to be effective and well tolerated for treating adult ULS in the Phase 2 JUNIPER study. The duration of response observed in JUNIPER suggests that DAXXIFY has the potential to reduce the frequency of adult ULS treatments by up to 50% annually. "As an investigator in the JUNIPER trial, I am delighted to present data from JUNIPER for the first time at this year's MDS Congress," said Atul Patel, MD, and Medical Director, Kansas Institute of Research. "The data indicates that duration for DaxibotulinumtoxinA for Injection is strong and has the potential to reduce the frequency of adult upper limb spasticity treatments, delivering improvement in patients' quality of life and the opportunity to expand treatment care. With current treatments, 60% of patients report spasticity symptoms return less than 3 months after treatment. 1 The need for a new treatment option is considerable as patients have overwhelmingly indicated the desire for a longer lasting option."

ShowHide Related Items >><<
RVNC Revance
$26.15 /

-1.35 (-4.91%)

RVNC Revance
$26.15 /

-1.35 (-4.91%)

09/09/22 Mizuho
Revance price target raised to $30 from $26 at Mizuho
09/09/22 Barclays
Revance price target raised to $35 from $22 at Barclays
09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
09/08/22 Needham
Revance price target raised to $35 from $25 at Needham
RVNC Revance
$26.15 /

-1.35 (-4.91%)

  • 13
    Sep
RVNC Revance
$26.15 /

-1.35 (-4.91%)

Syndicate
Revance 8M share Spot Secondary priced at $25.00 » 06:19
09/13/22
09/13
06:19
09/13/22
06:19
RVNC

Revance

$28.08 /

-0.41 (-1.44%)

Goldman Sachs, Cowen and…

Goldman Sachs, Cowen and Guggenheim are acting as joint book running managers for the offering. The deal size was increased to $200M from $150M and priced at low end of $25.00-$26.00 range.

ShowHide Related Items >><<
RVNC Revance
$28.08 /

-0.41 (-1.44%)

RVNC Revance
$28.08 /

-0.41 (-1.44%)

09/09/22 Mizuho
Revance price target raised to $30 from $26 at Mizuho
09/09/22 Barclays
Revance price target raised to $35 from $22 at Barclays
09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
09/08/22 Needham
Revance price target raised to $35 from $25 at Needham
RVNC Revance
$28.08 /

-0.41 (-1.44%)

  • 13
    Sep
RVNC Revance
$28.08 /

-0.41 (-1.44%)

On The Fly
Fly Intel: After-Hours Movers » 18:24
09/12/22
09/12
18:24
09/12/22
18:24
PL

Planet Labs

$5.42 /

+0.08 (+1.50%)

, VNCE

Vince Holding

$7.59 /

+0.09 (+1.20%)

, ORCL

Oracle

$77.17 /

+1.17 (+1.54%)

, CPRX

Catalyst Pharmaceuticals

$15.14 /

+0.385 (+2.61%)

, LNG

Cheniere Energy

$160.79 /

-0.22 (-0.14%)

, RENT

Rent The Runway

$4.94 /

+0.45 (+10.02%)

, BRZE

Braze

$43.60 /

+0.26 (+0.60%)

, CDAK

Codiak

$1.68 /

-0.11 (-6.15%)

, RVNC

Revance

$28.08 /

-0.41 (-1.44%)

, WKME

WalkMe

$11.12 /

+0.08 (+0.72%)

Check out this evening's…

ShowHide Related Items >><<
WKME WalkMe
$11.12 /

+0.08 (+0.72%)

VNCE Vince Holding
$7.59 /

+0.09 (+1.20%)

RVNC Revance
$28.08 /

-0.41 (-1.44%)

RENT Rent The Runway
$4.94 /

+0.45 (+10.02%)

PL Planet Labs
$5.42 /

+0.08 (+1.50%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

LNG Cheniere Energy
$160.79 /

-0.22 (-0.14%)

CPRX Catalyst Pharmaceuticals
$15.14 /

+0.385 (+2.61%)

CDAK Codiak
$1.68 /

-0.11 (-6.15%)

BRZE Braze
$43.60 /

+0.26 (+0.60%)

PL Planet Labs
$5.42 /

+0.08 (+1.50%)

06/15/22 Craig-Hallum
Planet Labs price target lowered to $10 from $15 at Craig-Hallum
06/15/22 Needham
Planet Labs price target lowered to $8.00 from $10.50 at Needham
06/15/22 Benchmark
Planet Labs price target lowered to $11 from $15 at Benchmark
05/25/22 Benchmark
EOCL award watershed moment for BlackSky, GIS industry, says Benchmark
VNCE Vince Holding
$7.59 /

+0.09 (+1.20%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

09/12/22 Deutsche Bank
Oracle Q4 momentum continued into Q1, says Deutsche Bank
08/11/22 Guggenheim
Oracle initiated with a Buy at Guggenheim
07/08/22 Piper Sandler
Microsoft price target lowered to $312 from $352 at Piper Sandler
06/29/22 Exane BNP Paribas
Oracle upgraded to Outperform from Neutral at Exane BNP Paribas
CPRX Catalyst Pharmaceuticals
$15.14 /

+0.385 (+2.61%)

08/24/22 Roth Capital
Catalyst Pharmaceuticals downgraded on valuation at Roth Capital
08/24/22 Roth Capital
Catalyst Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
08/11/22 Truist
Catalyst Pharmaceuticals price target raised to $17 from $12 at Truist
08/11/22 H.C. Wainwright
Catalyst Pharmaceuticals price target raised to $18 from $12 at H.C. Wainwright
LNG Cheniere Energy
$160.79 /

-0.22 (-0.14%)

08/16/22 Barclays
Cheniere Energy price target raised to $186 from $160 at Barclays
08/05/22 Mizuho
Cheniere Energy price target raised to $167 from $159 at Mizuho
05/31/22 Wells Fargo
Wells Fargo downgrades Cheniere Energy Partners to Underweight on valuation
05/23/22 RBC Capital
Cheniere Energy price target raised to $178 from $151 at RBC Capital
RENT Rent The Runway
$4.94 /

+0.45 (+10.02%)

07/22/22 Piper Sandler
Rent The Runway price target lowered to $10 from $12 at Piper Sandler
07/21/22 KeyBanc
KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view
07/20/22 KeyBanc
Rent The Runway initiated with a Sector Weight at KeyBanc
06/29/22 Raymond James
Rent The Runway initiated with an Outperform at Raymond James
BRZE Braze
$43.60 /

+0.26 (+0.60%)

07/12/22 UBS
Braze initiated with a Buy at UBS
06/23/22 Cowen
Braze price target lowered to $54 from $60 at Cowen
06/15/22 Loop Capital
Braze price target lowered to $50 from $75 at Loop Capital
06/15/22 Barclays
Braze price target lowered to $50 from $75 at Barclays
CDAK Codiak
$1.68 /

-0.11 (-6.15%)

08/31/22 Goldman Sachs
Codiak downgraded to Neutral at Goldman Sachs amid portfolio reprioritization
08/31/22 Goldman Sachs
Codiak downgraded to Neutral from Buy at Goldman Sachs
02/22/22 Wedbush
Codiak price target lowered to $24 from $34 at Wedbush
02/11/22 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
RVNC Revance
$28.08 /

-0.41 (-1.44%)

09/09/22 Mizuho
Revance price target raised to $30 from $26 at Mizuho
09/09/22 Barclays
Revance price target raised to $35 from $22 at Barclays
09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
09/08/22 Needham
Revance price target raised to $35 from $25 at Needham
WKME WalkMe
$11.12 /

+0.08 (+0.72%)

08/12/22 BMO Capital
WalkMe price target raised to $14 from $10 at BMO Capital
06/07/22 Citi
WalkMe price target lowered to $18 from $22 at Citi
06/07/22 Morgan Stanley
WalkMe reinstated with an Equal Weight at Morgan Stanley
05/26/22 BMO Capital
WalkMe price target lowered to $10 from $14 at BMO Capital
WKME WalkMe
$11.12 /

+0.08 (+0.72%)

VNCE Vince Holding
$7.59 /

+0.09 (+1.20%)

RVNC Revance
$28.08 /

-0.41 (-1.44%)

RENT Rent The Runway
$4.94 /

+0.45 (+10.02%)

PL Planet Labs
$5.42 /

+0.08 (+1.50%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

LNG Cheniere Energy
$160.79 /

-0.22 (-0.14%)

CPRX Catalyst Pharmaceuticals
$15.14 /

+0.385 (+2.61%)

CDAK Codiak
$1.68 /

-0.11 (-6.15%)

BRZE Braze
$43.60 /

+0.26 (+0.60%)

  • 13
    Sep
  • 13
    Sep
  • 17
    Nov
  • 27
    Oct
RENT Rent The Runway
$4.94 /

+0.45 (+10.02%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

LNG Cheniere Energy
$160.79 /

-0.22 (-0.14%)

WKME WalkMe
$11.12 /

+0.08 (+0.72%)

RVNC Revance
$28.08 /

-0.41 (-1.44%)

RENT Rent The Runway
$4.94 /

+0.45 (+10.02%)

PL Planet Labs
$5.42 /

+0.08 (+1.50%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

LNG Cheniere Energy
$160.79 /

-0.22 (-0.14%)

CPRX Catalyst Pharmaceuticals
$15.14 /

+0.385 (+2.61%)

BRZE Braze
$43.60 /

+0.26 (+0.60%)

WKME WalkMe
$11.12 /

+0.08 (+0.72%)

RENT Rent The Runway
$4.94 /

+0.45 (+10.02%)

PL Planet Labs
$5.42 /

+0.08 (+1.50%)

ORCL Oracle
$77.17 /

+1.17 (+1.54%)

LNG Cheniere Energy
$160.79 /

-0.22 (-0.14%)

BRZE Braze
$43.60 /

+0.26 (+0.60%)

Syndicate
Revance announces $150M common stock offering » 16:04
09/12/22
09/12
16:04
09/12/22
16:04
RVNC

Revance

$28.00 /

-0.49 (-1.72%)

Revance Therapeutics…

Revance Therapeutics announced a proposed underwritten public offering of $150M of its common stock. Goldman Sachs, Cowen and Company, and Guggenheim Securities are acting as joint book-running managers for the proposed offering. Barclays Capital is also acting as a bookrunner for the proposed offering.

ShowHide Related Items >><<
RVNC Revance
$28.00 /

-0.49 (-1.72%)

RVNC Revance
$28.00 /

-0.49 (-1.72%)

09/09/22 Mizuho
Revance price target raised to $30 from $26 at Mizuho
09/09/22 Barclays
Revance price target raised to $35 from $22 at Barclays
09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
09/08/22 Needham
Revance price target raised to $35 from $25 at Needham
RVNC Revance
$28.00 /

-0.49 (-1.72%)

RVNC Revance
$28.00 /

-0.49 (-1.72%)

Recommendations
Revance price target raised to $30 from $26 at Mizuho » 06:44
09/09/22
09/09
06:44
09/09/22
06:44
RVNC

Revance

$25.29 /

+4.53 (+21.82%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan raised the firm's price target on Revance e Therapeutics to $30 from $26 and keeps a Buy rating on the shares. A "major overhang" has been lifted on Revance shares with the approval of Daxxify, which also provides a "transformative growth" driver for the company in the ~$1.7B U.S. cosmetic toxin market, Divan tells investors in a research note. The analyst expects Daxxify to be a major competitor given its best-in-class profile with the six-month median duration of effect in treating glabellar lines. He believes "the story is still in the early innings."

ShowHide Related Items >><<
RVNC Revance
$25.29 /

+4.53 (+21.82%)

RVNC Revance
$25.29 /

+4.53 (+21.82%)

09/09/22 Barclays
Revance price target raised to $35 from $22 at Barclays
09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
09/08/22 Needham
Revance price target raised to $35 from $25 at Needham
09/08/22 Cowen
Revance price target raised to $65 from $55 at Cowen
RVNC Revance
$25.29 /

+4.53 (+21.82%)

RVNC Revance
$25.29 /

+4.53 (+21.82%)

Recommendations
Revance price target raised to $35 from $22 at Barclays » 06:38
09/09/22
09/09
06:38
09/09/22
06:38
RVNC

Revance

$25.29 /

+4.53 (+21.82%)

Barclays analyst Balaji…

Barclays analyst Balaji Prasad raised the firm's price target on Revance Therapeutics to $35 from $22 and keeps an Overweight rating on the shares. The approval of Daxxify finally allows Revance to make its mark in the neurotoxin market, start capitalizing on synergies and paves the way for therapeutics, Prasad tells investors in a research note. The analyst raised his revenue forecasts for Revance to $1B-plus by 2030.

ShowHide Related Items >><<
RVNC Revance
$25.29 /

+4.53 (+21.82%)

RVNC Revance
$25.29 /

+4.53 (+21.82%)

09/09/22 H.C. Wainwright
Revance price target raised to $29 from $25 at H.C. Wainwright
09/08/22 Needham
Revance price target raised to $35 from $25 at Needham
09/08/22 Cowen
Revance price target raised to $65 from $55 at Cowen
09/08/22 Mizuho
Revance options imply 28% move on FDA decision, says Mizuho
RVNC Revance
$25.29 /

+4.53 (+21.82%)

RVNC Revance
$25.29 /

+4.53 (+21.82%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.